DCOY
Decoy Therapeutics Inc.

114
Mkt Cap
$2.89M
Volume
8,269.00
52W High
$415.80
52W Low
$5.20
PE Ratio
-0.02
DCOY Fundamentals
Price
$5.43
Prev Close
$5.42
Open
$5.27
50D MA
$7.24
Beta
0.14
Avg. Volume
31,333.02
EPS (Annual)
-$129.10
P/B
0.49
Rev/Employee
$0.00
$9.95
Loading...
Loading...
News
all
press releases
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline Decoy Therapeutics...
PR Newswire·18d ago
News Placeholder
More News
News Placeholder
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 PR Newswire CAMBRIDGE, Mass. and HOUSTON, April 6, 2026 Live video webcast...
PR Newswire·21d ago
News Placeholder
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire CAMBRIDGE, Mass. and HOUSTON, April 2, 2026 CAMBRIDGE, Mass. and HOUSTON, April 2, 2026 /PRNewswire/ --Decoy Therapeutics, Inc...
PR Newswire·25d ago
News Placeholder
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform Decoy Therapeutics Enters Strategic...
PR Newswire·2mo ago
News Placeholder
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split Decoy Therapeutics Announces 1-for-12 Reverse Stock Split PR Newswire CAMBRIDGE, Mass., March 5, 2026 CAMBRIDGE, Mass., March 5, 2026...
PR Newswire·2mo ago
News Placeholder
Decoy Therapeutics Joins Webull Corporate Connect Service Platform
Decoy Therapeutics Joins Webull Corporate Connect Service Platform Decoy Therapeutics Joins Webull Corporate Connect Service Platform PR Newswire CAMBRIDGE, Mass. and HOUSTON, Feb. 11, 2026 - Connect...
PR Newswire·2mo ago
News Placeholder
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial Decoy Therapeutics to Participate in the Corporate Connect Webinar Series...
PR Newswire·3mo ago
News Placeholder
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform Decoy Therapeutics Reaches Global...
PR Newswire·3mo ago
<
...
1
>

Latest DCOY News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.